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Background: Natural language processing (NLP) is an information retrieval technique that has been 
shown to accurately identify quality measures for colonoscopy. There are no systematic methods by 
which to track adherence to quality measures for ERCP, the highest risk endoscopic procedure widely 
used in practice. 
Aim: Our aim was to demonstrate the feasibility of using NLP to measure adherence to ERCP quality 
indicators across individual providers. 
Methods: ERCPs performed by 6 providers at a single institution from 2006 to 2014 were identified. 
Quality measures were defined using society guidelines and from expert opinion, and then extracted 
using a combination of NLP and data mining (eg, ICD-9 CM codes). Validation for each quality measure 
was performed by manual record review. Quality measures were grouped into preprocedure (5), intra-
procedure (6), and postprocedure (2). NLP was evaluated using measures of precision and accuracy. 
Results: A total of 23,674 ERCPs were analyzed (average patient age of 52.9 ± 17.8, 14,113 (59.6%) 
women). Among 13 quality measures, precision of NLP ranged from 84% to 100% with intraprocedure 
measures having lower precision (84% for precut sphincterotomy). Accuracy of NLP ranged from 90% to 
100% with intraprocedure measures having lower accuracy (90% for pancreatic stent placement).  
Conclusion: NLP in conjunction with data mining facilitates individualized tracking of ERCP providers for 
quality metrics without the need for manual medical record review. Incorporation of these tools across 
multiple centers may permit tracking of ERCP quality measures through national registries. 
 
Background 
Quality measurement of endoscopy is becoming the standard of care in the United States1-5 and may 
influence choice in provider, outcomes, and reimbursement5-7. ERCP, the highest risk endoscopic 
procedure in widespread practice,8 has not been extensively studied for individual, endoscopic-based 
quality measures9. Historically, ERCP quality has focused on provider or facility volume, with higher 
volumes associated with higher quality as defined by success and adverse event rates after adjusting for 
procedure indication10, 11. In 2006, the American Society for Gastrointestinal Endoscopy (ASGE) and the 
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American College of Gastroenterology (ACG) Task Force on Quality Endoscopy provided the first quality 
indicators for ERCP, many based on expert consensus9, and these were subsequently updated in 20141.  
Similar to colonoscopy, there are challenges in obtaining ERCP-based quality measures due to the time 
intensive nature of manual medical record review. Given this challenge in colonoscopy, several studies 
have demonstrated the feasibility of using natural language processing (NLP) to extract these measures 
from text documents in the medical record, with >90% accuracy for colonoscopy-specific measures12-16. 
We hypothesized that NLP, in conjunction with data mining using standard billing codes, could be used to 
track ERCP quality measures accurately and efficiently.  If successful, NLP could be incorporated into 
health systems that aim to monitor ERCP quality and provide feedback to providers, administrators, and 
payers in an effort to show adherence to national benchmarks; if needed, these data could be used to 
refine local practices through quality improvement initiatives17. 
The primary aim of this study was to measure the precision and accuracy of NLP in assessing ERCP-
specific quality measures.  The secondary aim was to provide pilot data on variability of adherence to 
quality benchmarks among individual providers at a single institution.17 
Methods 
After Institutional Review Board (IRB) approval, we identified ERCP procedure reports and related clinical 
data from January 1, 2006 through July 25, 2014.  
Data Sources 
ERCP procedure reports were identified from the Indiana Network for Patient Care (INPC), 18 which is a 
large regional health information exchange that obtains data from healthcare organizations and payers19, 
20
. The database houses more than 4 billion pieces of clinical data with over 160 million text reports.  All 
providers in this study work at a single center (Indiana University Health; University Hospital), a high-
volume referral center with approximately 3000 ERCP procedures performed annually.  All ERCP 
procedure reports are stored within the INPC and were created using a single point-and-click endowriter 
(Provation® MD; Wolters Kluwer).  Clinical and payer data sources facilitate pairing ERCP reports with 
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procedure indications (International Classification of Diseases, Ninth Revision, Clinical Modification, 
ICD9-CM). 
Natural Language Processing System 
The Regenstrief Institute has created an Apache Unstructured Information Management Applications 
(UIMA™)21 based NLP system (nDepth) that uses open-source applications for NLP processing released 
under the Apache license version 2.0.22  In addition to search, more advanced NLP techniques (e.g. 
negation, regular expressions, and standard terminologies) are available through the system and were 
used as part of this study. 
Selection of Quality Measures 
Quality measures were identified based on the 2014 ASGE/ACG Quality Indicators for ERCP that were 
reviewed and endorsed by the American Society for Gastrointestinal Endoscopy (ASGE), the American 
College of Gastroenterology (ACG), and the American Gastroenterological Association (AGA)1. Measures 
were categorized as (1) preprocedure, (2) intraprocedure, and (3) postprocedure. Four additional 
measures (pre-cut sphincterotomy, cannulation of the pancreatic duct, injection of the pancreatic duct, 
and pancreatic duct stent placement) were added from internal discussion among the authors for 
exploratory analysis (Table 1). Table 1 also includes all ASGE/ACG quality indicators that were not 
included in this study and rationale for their exclusion. We addressed rectal indomethacin as an 
alternative to pancreatic stenting by introducing quality measure (QM10^) that allows for either option 
within the endoscopy report. Quality measures that did not require text extraction via NLP were extracted 
by an INPC data manager. These quality measures were extracted using ICD9-CM) codes. 
Validation of Quality Measures identified by NLP 
Documents listed as “ERCP” within the INPC include both radiology interpretation of fluoroscopic images 
from ERCP, and the ERCP procedure report itself. These were separated using NLP and validated via 
manual review.  The ERCP procedure reports were used for analysis of quality measures.  Only the 
ERCP procedure reports were used for NLP analysis of quality measures. 
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We randomly separated the above ERCP procedure reports 1:1 into training (fully available for 
investigators to create NLP query) and testing (blinded to investigators) sets.  The training set of ERCP 
reports was used to create NLP algorithms in an iterative fashion. The NLP algorithms were used on the 
test documents (which were not reviewed during the algorithm development phase) to evaluate the ability 
of the system to accurately determine the expected finding. Independent training and test sets were used 
to avoid over-fitting the NLP algorithm. Figure 1 shows the flow of the documents and analysis for the 
study. 
All ERCP procedure reports were analyzed as part of Metrics 1-5 as they did not require a specific 
indication (ie, ICD code). Metrics 6-10 required ICD9-CM identification before NLP analysis using ERCPs 
performed for choledocholithiasis, defined by ICD9 codes 574.3* - 574.5*; procedures were excluded 
when one or more of the following codes were associated: (1) spasm of sphincter of Oddi (576.5), (2) 
acute pancreatitis (577.1), (3) 577.2 (cyst and pseudocyst of pancreas), (4) 577.1 (chronic pancreatitis), 
(5) 577.8 (other specified disease of pancreas), (6) 751.7 (anomalies of pancreas), and (7) 157.* 
(malignant neoplasm of pancreas).  We selected choledocholithiasis because this represents the most 
common indication for ERCP and requires selective biliary cannulation and common bile duct stone 
extraction. Within these procedures, rates of inadvertent pancreatic duct cannulation and injection may 
also denote technical proficiency in treating choledocholithiasis. NLP was not used for identification of 
choledocholithiasis due to the complexity of terms and the large variation within the procedure reports 
when discussing indication. 
NLP was used to identify individual endoscopists and all quality measures listed in Table 1. For each 
quality measure, we randomly selected 50 individual documents from the training set for which the quality 
measure was identified by NLP and 50 other documents for which the quality measure was not identified 
(Figure 1). A single expert gastroenterologist (TDI) reviewed all documents manually (different random 
selection for each quality measure) from the NLP search and assessed true positives (TP, those 
documents that were appropriately identified by the search) and true negatives (TN, those documents 
without the presence of the quality measure by NLP). The precision (True positives/50) and accuracy of 
the NLP search for each quality measure were assessed based on the manually reviewed documents. 
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We estimated that 50 documents were sufficient for procedure identification given the high prevalence of 
the measures within the dataset as well as our previous experience with NLP validation for colonoscopy12, 
23
. A formal power calculation was not performed due to inability to know the percentage of the various 
outcomes a priori. In total, nearly 1,500 ERCP endoscopy reports were reviewed for the validation. 
Extraction of other Quality Measures 
Metric “1” (appropriateness of indication) was searched according to ICD-9 CM codes based on the multi-
society recommendations for appropriate indications1. Appropriate codes were identified by rating the 
indication as highly appropriate or potentially appropriate. These codes were rated if they had more than 
100 instances of being used in the first or second position of billing within 7 days of an ERCP procedure. 
Additional codes were added based on the known appropriate indications despite having fewer than 100 
instances of being used. ICD9-CM codes for Metric 1 are listed in Appendix 1 (available online). NLP was 
not used for Metric 1 as the variety of potential indications was too large to validate in this study. Metric 
“12” for perforation related to the procedure was determined based on ICD-9 CM codes including 
perforation of bile duct (576.3) and perforation of intestine (569.83) within 7 days of ERCP procedure. The 
metric rate was calculated as the number of perforations / the number of total ERCP by provider and in 
aggregate. Metric “13” for significant post-sphincterotomy bleeding was determined based on ICD-9 code 
acute post-hemorrhagic anemia (285.1) within 7 days of procedure. The metric rate was no. of bleeding 
events / no. of total ERCPs by provider and in aggregate. 
Two priority measures endorsed in the society guidelines were not included in this analysis: (1) 
technically successful placement of a bile duct stent and (2) rate of post-ERCP pancreatitis.  We chose 
not to measure stent placement given the diversity of indications for this maneuver, and post-ERCP 
pancreatitis requires a more deliberate prospective study design to measure accurately. 
Analysis 
Statistical analysis was performed to quantify the precision and accuracy of NLP for each quality 
measure. Precision (similar to positive predictive value): True positives / Test outcome positives over 
the 50 reviewed documents. Accuracy: True positives + True negatives / Total population of 100 
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reviewed documents. Because the entire document set (n = 63,119 ERCP procedures) was not manually 
annotated for a criterion standard, a true sensitivity (reports in agreement/positive reports by manual 
review) could not be calculated. 
After the 6 providers were identified by NLP, individualized quality metrics were extracted. For each 
provider, patient characteristics including age, gender, and race were summarized using mean and 
standard deviations for continuous variables and frequency and proportions for categorical variables. For 
binary quality metrics, unadjusted rates for each provider were calculated using proportions and 
compared using the Pearson chi-square test. For the number of ERCPs performed per year, mean and 
standard deviation of annual procedural volume were calculated over the study period; providers were 
compared using the ANOVA F-test.  All statistical analyses were performed using SAS 9.4 (SAS Institute, 
Cary, NC). 
Results 
Of 63,119 documents on 15,581 patients that were indexed as an “ERCP” document, 39,440 were 
excluded with 100% accuracy, as keyword text search indicated that these documents were radiology 
reports or other nonprocedure reports.  This resulted in 23,679 ERCP procedures on 13,299 patients 
identified by NLP (Figure 1). Validation of this methodology showed all reviewed documents to be true 
ERCP procedure reports written by an endoscopist (eg, not a radiology report). Of 23,679 ERCP 
procedures, 5 were missing patient age, gender, or race and hence were excluded as having incomplete 
data and not available for adjustment. The remaining 23,674 procedures comprised the final study 
sample used to evaluate the quality measures across the 6 providers. Each provider averaged more than 
280 ERCPs per year with a range of 282.7 to 570.9. The mean age of patients was 52.9 (17.8) years; 
59.6% were women and the majority (75.9%) were white (Supplementary Table 1, available online). 
Precision and accuracy of NLP in measuring ERCP quality measures 
Table 2 shows the precision and accuracy of NLP for each quality indicator. Precision ranged from 84% 
to100% with intra-procedure measures having lower values. Accuracy ranged from 90% to 100% with 
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intra-procedure measures having lower accuracy. We excluded seventeen documents post-hoc because 
the primary provider listed on the procedure note was a trainee (n=9) or rarely performed ERCP (n=8). 
 Across the 6 providers and after adjusting for age, sex, and race, variability in adherence to the 13 
ERCP-specific quality measures evaluated is illustrated in Figure 2.  For those metrics with available, 
society-recommended benchmark rates, all providers met or nearly met (as defined by an overlapping 
standard error) their targets for documentation of informed consent, appropriate indication, achievement 
of deep cannulation, complete extraction of common bile duct stones <1 cm, perforation rate, and 
hemorrhage rate.  Benchmark rates for appropriate documentation of the pre-procedure history and 
physical examination and risk of adverse events were not met by any of the 6 providers.  
Exploratory quality measures 
Four additional potential quality measures were also evaluated within ERCPs performed for 
choledocholithiasis.  Rates of unintended pancreatic duct cannulation and injection were significantly 
varied among the 6 providers, ranging from 15.6% to 26.0% and 8.7% to 22.6%, respectively (P < 0.0001 
for each. The rate of precut sphincterotomy to achieve deep bile duct cannulation was <4% for all 
providers, ranging from 1.1% to 4.0% (p < 0.0001). 
DISCUSSION 
ERCP is a challenging procedure with high risk for adverse events and technical failure. The risks 
increase exponentially when the procedure is performed for non-obstructive indications (eg, sphincter of 
Oddi dysfunction or idiopathic acute pancreatitis).  Feedback to colonoscopists on their adenoma 
detection rate (ADR) may or may not improve provider performance17, 24. It is plausible that feedback to 
ERCP providers on their adherence to national recommendations would also improve the quality of ERCP 
services provided. The primary objective of this study was to develop a feasible method to track quality 
metrics in ERCP.  An example of a stoplight report card is shown in Figure 3. Using an existing open-
source based NLP system, we extracted quality measures over an 8.5-year period and compared them 
across individual providers and with society guidelines. This work is the first attempt to assess ERCP 
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quality measures using NLP, and supports the feasibility of applying these techniques to larger datasets 
across multiple health-care systems. 
In this study we demonstrate clinically significant variation in rate of pancreatic cannulation when not the 
intended target among providers, even among a highly skilled group of endoscopists at a single referral 
center (>9% variation). Given that one of the high risks for ERCP is development of post-ERCP 
pancreatitis, this may be a high-impact process quality metric even among high-volume providers of 
ERCP. This knowledge may guide quality improvement projects to enhance appropriate documentation 
and identify providers who are not meeting society-endorsed benchmarks. The majority of quality 
measures show little to no variation in this highly homogeneous population of high-volume providers. 
Although many of the measures (eg, document pre-procedure H&P) may not reflect quality as these are 
often done externally to the report, they are contained within the quality tracking measurements for all 
endoscopic procedures.  
Two priority measures included in the society guideline were not included in this study: rate of bile duct 
stent placement and rate of post-ERCP pancreatitis. We did not include stent placement because the 
study population used to analyze intraprocedural quality metrics was limited to patients undergoing ERCP 
for choledocholithiasis, which is the most common indication for ERCP. In addition, post-ERCP 
pancreatitis cannot be reliably detected in a retrospective study design; given the concern for detection 
bias, we decided to exclude post-ERCP pancreatitis from this pilot study. 
The study has several limitations. First, the sample is restricted to ERCPs performed at a regional referral 
center. Although this high-volume unit does not reflect the general patient population, adherence to 
quality measures should apply to all ERCP providers.  Furthermore, this study seeks to develop and 
validate a feasible method for assessing ERCP quality measures, and not to report adherence to 
benchmarks established by society guidelines.  
A second limitation relates to the methodology used to define appropriate indication for ERCP.  The 
spectrum of indications and their appropriateness will require further study and more detailed manual 
record review; it is possible that lower rates observed in this pilot study could be attributable to the 
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definition of appropriate indication (see Appendix). Additionally, future studies will need to refine the 
definition using ICD-10-CM definitions. 
A third limitation is that a single endoscopy software (Provation MD; Wolters Kluwer) was used during the 
study period. This greatly enhances the ability for text mining and natural language processing to 
accurately detect specific concepts (eg, 100% accuracy for providers). However, our group has shown 
that this technique can be applied to other institutions and accurately measure variables despite different 
methods for text document entry (eg, dictation and endoscopy software)16. We also made assumptions 
about ICD-9-CM coding in relation to the procedure. This can be seen with the post-sphincterotomy 
bleeding rate allowing for 7 days after the procedure for any event associated with a specific ICD-9-CM 
code (285.1). With this assumption we may pick up non-ERCP related bleeding and/or bleeding not due 
to sphincterotomy. Additional ICD-9-CM or ICD-10-CM coding such as 578.9 (GI bleeding) and 998.11 
(hemorrhage complicating a procedure) might be used in the future to expand the identification of delayed 
adverse events. 
We believe NLP is unlikely to provide a solution for accurate assessment of quality metrics without 
additional input of other methods such as data mining of discrete elements (eg, billing and procedure 
codes).  However, given the breadth of maneuvers and outcomes specific to ERCP, NLP provides a 
standardized tool that could be applied across different platforms for procedure documentation.  The 
optimal combination may be to incorporate NLP into a multifaceted approach to data extraction and 
summation. 
Conclusion 
Overall, this study demonstrates that NLP, in conjunction with data mining of ICD codes, has the ability to 
track some quality measures, especially intra-procedure. However, the ability to accurately extract several 
peri-procedural quality measures (ie, post-ERCP pancreatitis) from the electronic record is unclear and 
requires further study. Future studies will need to refine this methodology and apply it to a larger number 
of providers and institutions, with the long-term goal being accurate tracking and reporting of ERCP 
quality.  
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Table 1. Quality measures for ERCP and method of extraction studied as well as non-included measures from ASGE/ACG guidelines. 
Metric # Quality Indicator Grade of 
Recommendation 
per Society 
Guidelines1 
Society 
Guideline 
Priority 
Measure1 
Performance 
Target 
Extraction 
Method 
Reason for 
Exclusion (if 
applicable) 
Preprocedure 
1 Endoscopy is performed 
for an appropriate 
indication 
1C+ Yes > 80% ICD-9 CM  
2 Informed consent is 
obtained and fully 
documented^  
3 No > 98% NLP 
3 Pre-procedure history and 
directed physical 
examination are 
performed and 
documented 
3 No > 98% NLP 
4 Risk for adverse events is 
assessed and 
documented before 
sedation is started^ 
3 No > 98% NLP 
5 Volume of ERCPs 
performed per year by 
endoscopist 
1C No > 100 NLP 
Intraprocedure 
6 Deep cannulation of the 
ducts of interest is 
documented* 
1C Yes > 98% NLP and 
ICD-9 CM 
 
7 Common bile duct stones 
<1 cm in patients with 
normal bile duct anatomy 
are extracted successfully 
and documented* 
1C Yes ≥ 90% NLP and 
ICD-9 CM 
8$ Pancreatic cannulation 
when not an intended 
target* 
n/a No n/a NLP and 
ICD-9 CM 
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9$ Pancreatic injection when 
not an intended target* 
n/a No n/a NLP and 
ICD-9 CM 
10$ Pancreatic stent 
placement if pancreatic 
duct cannulated 
n/a No n/a NLP  
11$ Precut sphincterotomy for 
cannulation 
n/a No n/a NLP 
Postprocedure 
12 Perforation due to ERCP 
(within 7 days) 
2C No ≤ 0.2 ICD-9 CM  
13 Rate of clinically 
significant hemorrhage 
after ERCP with or without 
sphincterotomy (within 7 
days) 
1C No < 1 ICD-9 CM 
Not included 
in this study 
 Frequency with which 
appropriate antibiotics for 
ERCP are administered for 
settings in which they are 
indicated 
2B No > 98%  Medications are not 
documented within 
the procedure notes 
and would be 
identified from 
pharmacy records 
for administration. 
Frequency with which 
ERCP is performed by an 
endoscopist who is fully 
trained and credentialed 
to perform ERCP 
3 No > 98% All providers studied 
(n=6) are high-
volume fully trained 
and credentialed 
physicians who 
perform ERCP. 
Frequency with which 
fluoroscopy time and 
radiation dose are 
measured and 
documented 
2C No > 98% This would be 
captured in 
alternative 
electronic systems 
and is not within the 
ERCP report. 
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Frequency with which 
stent placement for biliary 
obstruction in patients 
with normal anatomy 
whose obstruction is 
below the bifurcation is 
successfully achieved and 
documented 
1C Yes > 98% This study is limited 
to patients with 
choledocholithiasis. 
Frequency with which a 
complete ERCP report 
that details the specific 
techniques performed, 
particular accessories 
used, and all intended 
outcomes is prepared 
3 No > 98% All reports are 
created in this study 
using a template 
endoscopy software 
and include 
generalized 
descriptions of the 
accessories used. 
Frequency with which 
acute adverse events and 
hospital transfers are 
documented 
3 No > 98% This would be better 
studied with further 
clinical data not 
available within the 
ERCP report. 
Rate of post-ERCP 
pancreatitis 
1C Yes n/a Rate of post-ERCP 
pancreatitis requires 
prospective 
evaluation for 
accurate capture. A 
retrospective 
assessment, as in 
this paper, would 
have 
underrepresented 
the actual incidence 
of post-ERCP 
pancreatitis due to 
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detection bias. 
 
* For indication of choledocholithiasis (ICD-9 CM 574.3*, 574.4*, 574.5*) with exclusions of sphincter of Oddi dysfunction or pancreatic pathology 
by ICD-9 CM and NLP. 
$ These measures were added by the co-authors as exploratory metrics. 
^ Measures 2 and 4 are taken from the guidelines1 and are differentiated by the directed statement for “informed consent” or synonyms versus 
“risks and benefits were discussed”.  
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Table 2. Validation metrics for natural language processing on ERCP quality measures with 100 
documents reviewed per measure. 
Measure True 
Positive % 
True 
Negative 
% 
Testing Set 
Accuracy % 
Testing Set 
Precision 
ERCP Procedure 
Report 
100 100 100 1 
Correct  Provider (each 
tested separately) 
100 100 100 1 
Preprocedure 
Endoscopy is 
performed for an 
appropriate indication 
(QM1) 
n/a n/a n/a n/a 
Informed consent is 
obtained and fully 
documented (QM2) 
100 100 100 1 
Pre-procedure history 
and directed physical 
examination are 
performed and 
documented (QM3) 
100 100 100 1 
Risk for adverse events 
is assessed and 
documented before 
sedation is started 
(QM4) 
100 100 100 1 
Volume of ERCPs 
performed per year by 
endoscopist (QM5) 
n/a n/a n/a n/a 
Intraprocedure 
Deep cannulation of the 
ducts of interest is 
documented (QM6)* 
100 94 97 1 
Common bile duct 
stones <1 cm in 
patients with normal 
bile duct anatomy are 
extracted successfully 
and documented 
(QM7)* 
98 80 96.4 98 
Pancreatic cannulation 
when not an intended 
target (QM8)* 
96 100 98 96 
Pancreatic injection 
when not an intended 
target (QM9)* 
96 92 94 96 
Pancreatic stent 
placement if pancreatic 
duct cannulated 
(QM10)* 
92 88 90 92 
Precut sphincterotomy 
for cannulation (QM11) 
84 98 91 84 
Postprocedure 
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Perforation due to 
ERCP (within 7 days) 
(QM12) 
n/a n/a n/a n/a 
Rate of clinically 
significant hemorrhage 
after ERCP with or 
without sphincterotomy 
(within 7 days) (QM13) 
n/a n/a n/a n/a 
 
Precision (similar to positive predictive value): True positives / Test outcome positives over the 50 
reviewed documents.  
Accuracy: True positives + True negatives / Total population of 100 reviewed documents. 
* Testing was done on documents with an indication of choledocholithiasis. 
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Figure 1. Study flow and methods. 
ERCP procedure reports were identified through the INPC and separated into training and testing sets (panel A).  Some quality measures were 
assessed using all ERCP indications (measures 1-5 and 11-13); others required the indication of choledocholithiasis (measures 6-10). For each 
quality measure, 50 reports with and 50 reports without the measure identified were randomized extracted and reviewed manually (panel B). 
 
Figure 2. Adjusted provider specific quality measurements for ERCP with 95% confidence intervals. *Dashed line represents quality measure 
target. 
• Indication = Endoscopy is performed for an appropriate indication 
• Informed Consent = Informed consent is obtained and fully documented 
• H & P = Pre-procedure history and directed physical examination are performed and documented 
• Adverse Events = Risk for adverse events is assessed and documented before sedation is started 
• Deep Cannulation = Deep cannulation of the ducts of interest is documented 
• < 1 cm Stone = Common bile duct stones <1 cm in patients with normal bile duct anatomy are extracted successfully and documented 
• Panc Cannulation = Pancreatic cannulation when not an intended target 
• Panc Injection = Pancreatic injection when not an intended target 
• Panc Stent = Pancreatic stent placement if pancreatic duct cannulated 
• Stent or Indomethacin = Pancreatic stent placement or indomethacin given if pancreatic duct cannulated 
• Precut = Precut sphincterotomy for cannulation 
• Perforation = Perforation due to ERCP (within 7 days) 
• Hemorrhage = Rate of clinically significant hemorrhage after ERCP with or without sphincterotomy (within 7 days) 
 
 
Figure 3. Example provider quality report card based on Provider 1 overall measure. Green is for being above the benchmark including 95% CI. 
Yellow includes the benchmark in the 95% CI. Red is below the benchmark including the 95% CI.  
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Appendix 
ICD-9 CM Inclusion for Metric 1 
Appropriate Indication codes included; calculus of bile duct (574.3*, 574.4*, 574.5*), cholangitis 
(576.1), obstruction of bile duct (576.2 ), fistula of bile duct (576.4), spasm of sphincter of Oddi (576.5), 
other specified disorders of biliary tract (576.8), acute pancreatitis (577.1), 577.2 (cyst and pseudocyst of 
pancreas), 577.1 (chronic pancreatitis), 577.8 (other specified disease of pancreas), 751.7 (anomalies of 
pancreas), 157.* (malignant neoplasm of pancreas), 156.* (malignant neoplasm of gallbladder and 
extrahepatic bile ducts), and 155.* (malignant neoplasm of liver and  intrahepatic bile ducts). All codes 
were linked to an appropriate ERCP related CPT code within the data set. The metric rate was number of 
appropriately identified ERCP / number of total ERCP by provider and in aggregate. 
ICD-9 CM Inclusion for Metric 6-9 
Inclusion codes were calculus of bile duct (574.3*, 574.4*, 574.5*) with exclusion codes of spasm 
of sphincter of Oddi (576.5), acute pancreatitis (577.1), 577.2 (cyst and pseudocyst of pancreas), 577.1 
(chronic pancreatitis), 577.8 (other specified disease of pancreas), 751.7 (anomalies of pancreas), and 
157.* (malignant neoplasm of pancreas).  
Creation of Risk Adjusted Quality Scores 
The adjusted proportions for each quality measure were estimated proportions based on the 
logistic regression model where patients for the six providers were similar in terms of age, gender, and 
race. Specifically, these proportions were calculated for specified levels of the covariates that were found 
in the data across all providers. They could be easily calculated using the LSMEANS statement in the 
SAS LOGISTIC procedure with the OM option.   
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Appendix Table 1. Breakdown of ERCP procedures within dataset. 
 
Provider # of ERCP 
Per Year 
Rate (Std) 
# of 
Patients Age (Std) Female  White 
Provider 1 1696 282.7 (113.3) 1060 53.7 (17.6) 991 (58.5%) 1266 (74.6%) 
Provider 2 5133 570.4 (194.5) 3084 51.9 (18.0) 3174 (61.8%) 3946 (76.9%) 
Provider 3 4455 495.3 (192.9) 3103 51.6 (17.0) 2812 (63.1%) 3460 (77.7%) 
Provider 4 2680 297.9 (83.7) 1804 56.3 (17.3) 1497 (55.9%) 1998 (74.6%) 
Provider 5 5138 570.9 (157.9) 2507 52.9 (18.1) 3025 (58.9%) 3920 (76.3%) 
Provider 6 4572 508.0 (137.5) 2935 52.8 (17.9) 2614 (57.3%) 3386 (74.1%) 
P Value < 0.001 Not felt to be clinically significant 
 
 
